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Abstract: BACKGROUND Over the past decades, stroke risk associated with carotid disease has de-
creased, reflecting improvements in medical therapy and a more rigorous control of vascular risk factors.
It is less clear whether the procedural risk of carotid revascularization has declined over time. METH-
ODS We analyzed temporal changes in procedural risks among 4597 patients with symptomatic carotid
stenosis treated with carotid artery stenting (n=2326) or carotid endarterectomy (n=2271) in 4 ran-
domized trials between 2000 and 2008, using generalized linear mixed-effects models with a random
intercept for each source trial. Models were additionally adjusted for age and other baseline charac-
teristics predicting treatment risk. The primary outcome event was any procedural stroke or death,
occurring during or within 30 days after revascularization. RESULTS The procedural stroke or death
risk decreased significantly over time in all patients (unadjusted odds ratio per year, 0.91; 95% CI,
0.85-0.97; P=0.006). This effect was driven by a decrease in the carotid endarterectomy group (un-
adjusted odds ratio per year, 0.82; 95% CI, 0.73-0.92; P=0.003), whereas no significant decrease was
found after carotid artery stenting (unadjusted odds ratio, 0.96; 95% CI, 0.88-1.04; P=0.33). Carotid
endarterectomy patients had a lower procedural stroke or death risk compared with carotid artery stent-
ing patients, and the difference significantly increased over time (interaction P=0.031). After adjust-
ment for baseline characteristics, the results remained essentially the same. CONCLUSIONS The risk
of stroke or death associated with carotid endarterectomy for symptomatic carotid stenosis decreased
over an 8-year period, independent of clinical predictors of procedural risk. No corresponding reduction
in procedural risk was seen in patients treated with stenting. CLINICAL TRIAL REGISTRATION
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BACKGROUND: Over the past decades, stroke risk associated with 
carotid disease has decreased, reflecting improvements in medical therapy 
and a more rigorous control of vascular risk factors. It is less clear whether 
the procedural risk of carotid revascularization has declined over time.
METHODS: We analyzed temporal changes in procedural risks 
among 4597 patients with symptomatic carotid stenosis treated with 
carotid artery stenting (n=2326) or carotid endarterectomy (n=2271) 
in 4 randomized trials between 2000 and 2008, using generalized 
linear mixed-effects models with a random intercept for each source 
trial. Models were additionally adjusted for age and other baseline 
characteristics predicting treatment risk. The primary outcome event was 
any procedural stroke or death, occurring during or within 30 days after 
revascularization. 
RESULTS: The procedural stroke or death risk decreased significantly 
over time in all patients (unadjusted odds ratio per year, 0.91; 95% CI, 
0.85–0.97; P=0.006). This effect was driven by a decrease in the carotid 
endarterectomy group (unadjusted odds ratio per year, 0.82; 95% CI, 0.73–
0.92; P=0.003), whereas no significant decrease was found after carotid 
artery stenting (unadjusted odds ratio, 0.96; 95% CI, 0.88–1.04; P=0.33). 
Carotid endarterectomy patients had a lower procedural stroke or death 
risk compared with carotid artery stenting patients, and the difference 
significantly increased over time (interaction P=0.031). After adjustment for 
baseline characteristics, the results remained essentially the same.
CONCLUSIONS: The risk of stroke or death associated with carotid 
endarterectomy for symptomatic carotid stenosis decreased over an 
8-year period, independent of clinical predictors of procedural risk. No 
corresponding reduction in procedural risk was seen in patients treated 
with stenting.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov; 
http://www.isrctn.com. Unique identifier: NCT00190398 (EVA-3S), 
NCT00004732 (CREST), ISRCTN57874028 (SPACE), and ISRCTN25337470 
(ICSS).
VISUAL OVERVIEW: A visual overview is available for this article.
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O
ver the past decades, the risk of stroke asso-
ciated with carotid disease appears to have 
decreased,1 reflecting improved medical care 
and risk factor control. In some patients, the risk of 
stroke under conservative management may be so low 
that the risks associated with carotid revascularization 
are no longer justified. This is of relevance for patients 
with asymptomatic carotid stenosis but potentially 
also for patients with symptomatic carotid stenosis. 
On the contrary, the procedural risk associated with 
carotid revascularization may also have decreased over 
time preserving the net benefit of invasive treatment. 
The evidence to support or refute such a trend is cur-
rently limited.
We conducted an analysis of the temporal change in 
procedural stroke or death risks associated with carotid 
endarterectomy (CEA) and carotid artery stenting (CAS) 
in the 4 large randomized controlled trials that enrolled 
patients with symptomatic carotid stenosis between 
2000 and 2008, using data at individual patient 
level.2–5 We hypothesized that procedural risks associ-
ated with carotid artery revascularization would have 
declined over time. In addition, we assumed that risks 
of CAS might have decreased more strongly than CEA 
risks because of technical development and increasing 
experience.
METHODS
The data that support the findings of this study are avail-
able from the corresponding author on reasonable request. 
This meta-analysis includes individual patient data from 
EVA-3S (Endarterectomy Versus Angioplasty in Patients With 
Symptomatic Severe Carotid Stenosis; unique identifier: 
NCT00190398), SPACE (Stent-Protected Angioplasty Versus 
Carotid Endarterectomy; unique identifier: ISRCTN57874028), 
CREST (Carotid Revascularization Endarterectomy Versus 
Stenting Trial; unique identifier: NCT00004732), and ICSS 
(International Carotid Stenting Study; unique identifier: 
ISRCTN25337470).2–5 We excluded trials that included only 
asymptomatic stenosis, patients deemed at high risk from 
CEA, and those recruiting <300 patients. Ethics approval 
for the contributing trials was obtained at the competent 
institutional review boards, and all patients provided written 
informed consent. The pooled analysis of individual patient 
data was agreed on at the design stage of these trials. The 
present analysis was prespecified during one of the regular 
steering committee meetings of the Carotid Stenosis Trialists’ 
Collaboration by representatives from the involved trials. All 
4 trials randomly allocated patients with symptomatic mod-
erate-to-severe carotid stenosis (≥50% reduction of lumen 
diameter measured according to the method used in NASCET 
[North American Symptomatic Carotid Endarterectomy 
Trial]6), who were equally suitable for either CAS or CEA and 
considered to be at standard procedural risk. The definition 
of symptomatic carotid stenosis was symptoms attributable 
to the relevant carotid artery within 120 days before random-
ization in EVA-3S, within 180 days before randomization in 
CREST, within 6 months before randomization in SPACE, and 
within 12 months before randomization in ICSS. CREST addi-
tionally included patients with asymptomatic carotid stenosis, 
but these patients were excluded from the present analysis.
In EVA-3S, SPACE, and ICSS, any stent with a Conformité 
Européenne mark could be used. In CREST, the protocol 
specified the use of RX Acculink stent. In EVA-3S the use 
of distal filter protection devices became mandatory early 
in the trial.7 In CREST, the protocol specified the use of the 
RX Accunet embolic protection device whenever feasible. 
In ICSS and SPACE, the use of protection devices remained 
optional throughout the trials. Surgeons were allowed to 
perform standard or eversion endarterectomy under local 
or general anesthesia, with or without the use of shunts 
or patches.
The primary outcome of the present analysis was any 
stroke or death occurring within 30 days after treatment. 
Stroke was defined as an acute deficit of focal neurological 
function, which led to symptoms lasting >24 hours, resulting 
from intracranial vascular disturbance (ischemia or hemor-
rhage). Because the trials contributing to this analysis differed 
in assessment and definition of procedural myocardial infarc-
tion, we did not include myocardial infarction in the primary 
outcome.
Statistical Analysis
The analysis population included all patients in whom the ran-
domly allocated treatment was initiated (per-protocol analy-
sis).8 The following baseline characteristics of patients from 
all 4 source trials were summarized descriptively for an early 
(2000–2004) and a late enrollment period (2005–2008): sex, 
patient age, modified Rankin Scale (mRS) at baseline, systolic 
blood pressure at baseline, history of hypertension, diabetes 
mellitus, lipid-lowering therapy (LLT), smoking (past or pres-
ent), coronary heart disease, degree of ipsilateral carotid 
WHAT IS KNOWN
• Over past decades, stroke risk associated with 
carotid disease has declined, most likely reflecting 
improvements in medical therapy and better con-
trol of vascular risk factors.
• Whether the procedural risk associated with revas-
cularization of carotid stenosis has also declined 
over time and whether any such temporal trend 
would differ between carotid endarterectomy and 
stenting was unclear.
WHAT THIS STUDY ADDS
• The risk of stroke or death associated with carotid 
revascularization in clinical trials has decreased 
over time.
• The decline in procedural risk was particu-
larly apparent in patients treated with carotid 
endarterectomy.
• No significant decline in procedural risk was found 
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stenosis according to NASCET criteria,6 presence of contra-
lateral carotid stenosis (≥70%) according to NASCET criteria6 
or occlusion, qualifying event (QE) type, and days from QE to 
treatment.
To investigate whether the risk of stroke or death within 
30 days of treatment changed over time, we used general-
ized linear mixed-effects models with binomial error and 
logit link function, with a random intercept for each source 
trial. We fitted one generalized linear mixed-effects model 
for all patients, using treatment received (CAS versus CEA), 
year of treatment (as a continuous variable), and the interac-
tion between treatment received and year of treatment as 
explanatory variables to investigate whether any difference in 
procedural risk between CAS and CEA changed over time. In 
addition, a separate generalized linear mixed-effects model 
with only year of treatment as explanatory variable was fit-
ted for each treatment group separately. To adjust our mod-
els, we identified those baseline patient characteristics that 
were most strongly associated with procedural risk for stroke 
or death, using backward model selection based on Akaike 
information criterion, in all patients and in each treatment 
group separately. We continued dropping variables from the 
multivariate models as long as the Akaike information crite-
rion for the reduced model was smaller than the Akaike infor-
mation criterion of the former model. Because of the high 
percentage of missing values, we did not include days from 
QE to treatment in the backward model selection. The models 
investigating the effect of time on procedural risk were subse-
quently adjusted for all baseline characteristics selected in this 
manner. We performed a post hoc sensitivity analysis adjust-
ing all models for days from QE to treatment. We defined 
an alpha level of 0.05 to ascribe statistical significance. No 
correction was made for multiple testing. All statistical analy-
ses were performed as complete case analyses (no imputation 
of missing values), using the statistical software environment 
R (version 3.4.1; R Foundation for Statistical Computing, 
Vienna, Austria).
RESULTS
In total, 4775 patients with symptomatic carotid steno-
sis were enrolled in the contributing trials. The pooled 
per-protocol analysis set included 4597 patients, 2271 
of whom received CEA and 2326 CAS (Figure  1). 
EVA-3S enrolled patients from 2000 to 2005, SPACE 
from 2001 to 2006, ICSS from 2001 to 2008, and 
CREST from 2000 to 2008. Baseline characteristics were 
well balanced between treatment groups as previously 
reported.2–5 The proportions of patients with a history 
of hypertension, coronary heart disease, smoking, and 
severe ipsilateral carotid stenosis were significantly 
higher in the later enrollment period (2005–2008) 
compared with the early enrollment period (2000–
2004; Table 1). The proportion of patients taking LLT 
significantly increased from 52.4% in the early enroll-
ment period to 74.1% in the late enrollment period. 
Level of functional disability measured by the mRS was 
higher, and the time from QE to treatment was shorter 
in the late enrollment period (Table 1).
Crude percentages of patients with the primary out-
come measure per year are shown in Table 2. In the 
CEA group, crude procedural risks were 7.1% between 
2000 and 2002 and 2.0% between 2007 and 2008. 
In the CAS group, crude risks were 8.2% between 
2000 and 2002 and 5.8% between 2007 and 2008 
(Table 2). The risk of stroke or death during the proce-
dural period for both treatments combined decreased 
significantly over time (unadjusted odds ratio [OR] per 
year, 0.91; 95% CI, 0.85–0.97; P=0.006). After adjust-
ment for baseline characteristics, which were indepen-
dently associated with the primary outcome in both 
treatment groups combined (age, mRS, hypertension, 
diabetes mellitus, and severe ipsilateral carotid steno-
sis; Table I in the Data Supplement), the decline in risk 
remained essentially unchanged (adjusted OR, 0.89; 
95% CI, 0.83–0.95; P<0.001). In the post hoc sen-
sitivity analysis additionally adjusting our models for 
days from QE to treatment, the results remained again 
essentially the same (OR, 0.91; 95% CI, 0.84–0.99; 
P=0.023).
In the CEA group alone, the risk of procedural stroke 
or death also decreased significantly over time, both in 
the unadjusted model (OR, 0.82; 95% CI, 0.73–0.92; 
P=0.003), in the model adjusted for mRS, hypertension, 
diabetes mellitus, coronary heart disease, ipsilateral 
severe carotid stenosis, and contralateral stenosis >50% 
or occlusion (OR, 0.82; 95% CI, 0.72–0.93; P=0.002), 
and in the model additionally adjusted for days from QE 
to treatment (OR, 0.81; 95% CI, 0.71–0.93; P=0.005).
In the CAS group alone, the change in procedural risk 
over time was not statistically significant in the unad-
justed model (OR, 0.96; 95% CI, 0.88–1.05; P=0.33), in 
the model adjusted for age, hypertension, LLT, smoking, 
and QE type (OR, 0.95; 95% CI, 0.87–1.05; P=0.28), or 
in the model additionally adjusted for days from QE to 
treatment (OR, 0.95; 95% CI, 0.86–1.06; P=0.38).
Patients receiving CEA were at lower risk of proce-
dural stroke or death than patients receiving CAS over 
the entire enrollment period (OR, 0.47; 95% CI, 0.35–
0.62; adjusted for year of treatment; OR, 0.46; 95% CI, 
0.35–0.62; adjusted for year of treatment, age, mRS at 
baseline, history of hypertension and diabetes mellitus, 
and severe ipsilateral carotid stenosis). This difference 
in procedural risk became more pronounced over time 
(unadjusted interaction: OR, 1.17; 95% CI, 1.02–1.35; 
P=0.031; adjusted interaction: OR, 1.16; 95% CI, 1.01–
1.34; P=0.038; Figures 2 and 3). The interaction was of 
similar magnitude but no longer statistically significant 
when additionally adjusting for days from QE to treat-
ment (OR, 1.13; 95% CI, 0.96–1.34; P=0.142).
DISCUSSION
In this meta-analysis of individual patient data from 
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or death associated with carotid revascularization for 
symptomatic carotid stenosis decreased significantly 
over time. When patients were analyzed separately by 
treatment, the decline in risk over time was only sta-
tistically significant in patients treated with CEA. This 
decrease in risk was independent of clinical risk factors.
Data from OxVasc (Oxford Vascular Study) showed a 
decline in age- and sex-specific stroke incidence in an 
unselected population in Oxfordshire, United Kingdom, 
between 1981 to 1984 and 2002 to 2004,9 coinciding 
with a significant increase in the use of blood pressure–
lowering, antiplatelet-lowering, and lipid-lowering 
medication between the 2 periods. Likewise, meta-
regression analyses suggested a decline in annual stroke 
risk associated with asymptomatic carotid stenosis over 
the past 20 years.1 Indirect evidence on a decline in 
stroke risk in patients with symptomatic carotid stenosis 
can be gathered from transient ischemic attack regis-
tries: the 90-day stroke risk after a transient ischemic 
attack caused by large artery atherosclerosis was consis-
tently reported to be around 20% in the last decade,10,11 
but dropped to merely 6% in a recent publication.12 
While some of this decrease may probably have been 
accounted for by more rapid specialized assessment 
and early carotid revascularization in selected patients, 
changes in medical therapy are also likely to be impor-
tant. A study from Denmark of patients with symptom-
atic carotid stenosis found a decline in the rate of any 
recurrent cerebrovascular event before carotid revascu-
larization from 29% to 2.5% after introduction of an 
optimized medical treatment regimen consisting of dual 
antiplatelet and statin therapy.13
In the original European and North American symp-
tomatic CEA trials establishing the benefit of CEA in 
patients with symptomatic carotid stenosis, only a 
minority of patients received statins.14 Since these tri-
als were conducted, medical therapy and risk factor 
management has improved, not only with more wide-
spread use of statins but also with stricter control of 
blood pressure and management of other risk fac-
tors. A lower stroke risk under conservative manage-
ment than observed in previous trials may obviate the 
need for invasive revascularization in many patients 
with symptomatic or asymptomatic carotid disease. 
On the contrary, any decline in the procedural risk of 
stroke or death associated with carotid revasculariza-
tion would act toward maintaining the net benefit of 
invasive treatment. Existing literature suggests a decline 
Figure 1. Study flowchart depicting all patients enrolled in the source trials included in meta-analysis, as well as events excluding patients from 
analysis. 
CREST indicates Carotid Revascularization Endarterectomy Versus Stenting Trial; EVA-3S, Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe 
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in procedural risk associated with CEA for asymptom-
atic carotid stenosis.15 However, reliable data on proce-
dural risks for symptomatic carotid stenosis have been 
sparse,16 and it remained unknown whether temporal 
changes differed between CAS and CEA.
Our findings now provide strong evidence for a 
decline in procedural stroke or death risk associated 
with revascularization of symptomatic carotid stenosis 
over time. The availability of data at individual patient 
level from several randomized clinical trials yielded 
important strengths. First, we were able to show tem-
poral changes with greater statistical power than was 
possible at the level of a single trial. Second, we were 
able to minimize the risk of confounding of the effect 
of time on procedural risk by a potential change in the 
characteristics of patients included in the trials during 
the course of enrollment. Some of the baseline risk fac-
tors that were associated with the procedural risk of 
stroke or death in both treatment groups combined 
(history of hypertension, disability measured by the 
mRS, and degree of ipsilateral carotid stenosis) became 
more prevalent in the later enrollment period. After 
adjusting for these risk factors, the results remained 
essentially the same.
A third strength of our study was that we were able 
to investigate whether any temporal trend in procedural 
risks would differ between CEA and CAS, owing to the 
randomized design of the source trials. Widespread use 
of CAS only started a few years before the start of the 
trials contributing to this meta-analysis. We, therefore, 
hypothesized that technical development and increas-
ing experience would lead to a stronger decline in pro-
cedural risk with CAS compared with CEA. Surprisingly, 
we found the opposite to be true. It is possible that 
investigators became more selective in the patients they 
included in the trials as enrollment went on, in terms of 
characteristics that were not measured. If this was the 
case, any such selection effect must have had a stronger 
impact on procedural risks of CEA than on risks of CAS. 
Previous studies suggest that neurophysiological moni-
toring and intraoperative assessment of the treated 
carotid artery during the CEA procedure became more 
frequent over time and that these factors are associ-
ated with a lower short-term stroke or death risk.17,18 It 
is possible that these factors were also of importance in 
our study population, but the data were not available 
for the present analysis. For CAS, however, with grow-
ing experience, interventionists might have accepted 
Table 1. Baseline Characteristics in the Early (2000–2004) and Late (2005–2008) Enrollment Period
2000–2004 (n=2044) 2005–2008 (n=2553) P Value
Male sex 69.8% 69.8% 0.995
Age, y (mean, SD) 69.2±9.4 69.3±9.1 0.669
Systolic blood pressure at baseline, mm Hg (mean, SD) 143.7±19.8 143.1±21.9 0.319
Hypertension 73.8% 77.0% 0.016
Diabetes mellitus 25.8% 24.4% 0.281
Lipid-lowering therapy 52.4% 74.1% <0.001
Smoking (current or past) 62.0% 67.3% <0.001
Coronary heart disease 26.2% 29.3% 0.025
mRS at baseline (median [IQR]) 0 (0–1) 1 (0–1) 0.02
Degree of ipsilateral carotid stenosis  <0.001
  Moderate (50%–69%) 22.4% 16.7%  
  Severe (70%–99%) 77.6% 83.3%  
Contralateral stenosis or occlusion 14.5% 15.0% 0.648
Qualifying event type  0.063
  Retinal ischemia 15.7% 18.3%  
  Transient ischemic attack 37.9% 36.0%  
  Hemispheric stroke 46.4% 45.8%  
Days from QE to treatment (median [IQR])* 32 (15–68) 26 (11–61) <0.001
Baseline characteristics of patients enrolled in the 4 source trials during the early enrollment period (2000–2004) and the late enrollment 
period (2005–2008). P values for differences in baseline characteristics between the early and the late enrollment period were calculated using 
Welch test for continuous variables, Wilcoxon rank-sum test for mRS (not normally distributed), and χ2 test for categorical variables. EVA-3S 
recorded LLT use at baseline, but patients were only considered to be taking LLT if started >3 mo before randomization. SPACE and CREST 
collected data on LLT use at randomization. ICSS did not collect information on LLT use at baseline but did collect these data at the 1-mo follow-
up, which were included in the table. CREST indicates Carotid Revascularization Endarterectomy Versus Stenting Trial; EVA-3S, Endarterectomy 
Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis; ICSS, International Carotid Stenting Study; IQR, interquartile range; 
LLT, lipid-lowering therapy; mRS, modified Rankin Scale; and SPACE, Stent-Protected Angioplasty Versus Carotid Endarterectomy.
*Date of the QE before randomization was not collected in SPACE initially, but for the pooled analysis, these dates were gathered where 
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patients in the trials with more difficult anatomy, which 
may have counteracted any learning-curve effect.
The CREST investigators have previously reported 
a nonsignificant decline in the procedural stroke or 
death risk associated with CAS over time, and an ini-
tial decrease followed by an increase in CEA risk for 
which there was no conclusive explanation.19 Of note, 
CREST initially included only patients with symptom-
atic carotid stenosis but then additionally allowed 
patients with asymptomatic carotid stenosis in the 
trial during the course of enrollment. This change in 
the proportion of the 2 groups limited the investiga-
tion of a temporal trend. The present, pooled analysis 
specifically focused on temporal changes in treatment 
risks in patients with symptomatic carotid stenosis, 
considered to be at normal surgical risk. Therefore, 
data of patients with asymptomatic carotid steno-
sis enrolled in CREST were not incorporated. For the 
same reason, we did not include data from trials com-
paring stenting versus endarterectomy in asymptom-
atic patients only (ACT-1 [Asymptomatic Carotid Trial 
1]) or in patients considered to be at elevated risk of 
procedural complications (SAPPHIRE [Stenting and 
Angioplasty With Protection in Patients at High Risk 
for Endarterectomy]).20,21 The combined analysis of 
data from 4 trials allowed for a more reliable inves-
tigation of temporal changes in treatment risks, and 
whether these differed between CAS and CEA, than 
was possible at the level of a single trial.
Embolus protection devices have been developed to 
prevent cerebral embolization during the CAS proce-
dure, in an effort to reduce the procedural risk of stroke. 
Of note, the trials included in the present analysis dif-
fered in their policies on embolus protection device use; 
in the CREST trial, use of a single filter-type device was 
mandatory. In the EVA-3S, SPACE, and ICSS trials com-
bined, embolus protection devices were used in 61% of 
patients treated with CAS (in 87% of cases, these were 
filter-type devices),22 but there was no significant differ-
ence in procedural stroke risk between patients treated 
with versus without an embolus protection device. 
However, more recent types of protection devices, 
exerting arrest or reversal of flow across the stenosis, 
which may be more effective than filter devices in pre-
venting stroke during CAS,23–26 were not widely used 
at the time of recruitment in these trials. Therefore, 
our study was not suited to detect an impact of such 
devices on stroke risk.
The question whether any change in procedural 
risk of carotid revascularization over time would be 
explained by an increased use of LLT was of particu-
lar interest. We found an increase of patients taking 
LLT from 52% in the early enrollment years to 74% in 
the late enrollment years. However, LLT did not explain 
procedural risk in the entire study population or in 
patients treated with CEA. LLT reduced procedural risk 
in patients treated with CAS, but the temporal change 
in CAS risk was not statistically significant either unad-
justed or adjusted for LLT and other risk factors.
Table 2. Procedural Risk for Stroke or Death Expressed as Crude Risks Over Time
Year of Treatment
All Patients (n=4597) Endarterectomy (n=2271) Stenting (n=2326)
Patients, n n (%) Patients, n n (%) Patients, n n (%)
2000–2002, n (%) 560 43 (7.7%) 280 20 (7.1%) 280 23 (8.2%)
2003, n (%) 659 43 (6.5%) 330 18 (5.5%) 329 25 (7.6%)
2004, n (%) 825 37 (4.5%) 411 13 (3.2%) 414 24 (5.8%)
2005, n (%) 919 58 (6.3%) 439 14 (3.2%) 480 44 (9.2%)
2006, n (%) 630 37 (5.9%) 310 13 (4.2%) 320 24 (7.5%)
2007–2008, n (%) 1004 39 (3.9%) 501 10 (2.0%) 503 29 (5.8%)
Total 4597 257 (5.6%) 2271 88 (3.9%) 2326 169 (7.3%)
Total numbers of patients recruited, as well as numbers of patients and crude percentages of patients with the primary outcome measure per year for all patients, 
patients treated with endarterectomy, and patients treated with carotid stenting separately. The years 2000 to 2003 and 2007 to 2008 were pooled because of the 
relatively small number of patients enrolled.
Figure 2. Decline in risk of stroke or death over time–—unadjusted 
model.  
Modeled risks of stroke or death occurring within 30 d after treatment over 
time by treatment group in the unadjusted generalized linear mixed-effects 
model. Open and closed circles represent fitted values from the model. Error 
bars represent Bayesian 95% credible intervals. The interaction between 
type of treatment and year of treatment was statistically significant (interac-
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As both risk of stroke and procedural risk of revas-
cularization appear to be lower than at the time of the 
initial CEA trials, substantial uncertainty remains as to 
which patients will still benefit from carotid revascular-
ization in addition to contemporary medical therapy 
and risk factor management. Several randomized tri-
als are currently investigating this question, includ-
ing the ECST-2 (Second European Carotid Surgery 
Trial), the SPACE-2, the CREST-2, and the ACTRIS tri-
als (Endarterectomy Combined With Optimal Medical 
Therapy Versus Optimal Medical Therapy Alone in 
Patients With Asymptomatic Severe Atherosclerotic 
Carotid Artery Stenosis at Higher-Than-Average Risk 
of Ipsilateral Stroke). Of note, about 1 in 5 patients in 
our study population had moderate degree of stenosis 
(50%–69%). Degree of stenosis is but one of several 
factors known to predict stroke risk in patients with 
symptomatic carotid stenosis. Risk models including 
demographic factors, vascular risk factors, degree of 
stenosis, and plaque morphology help identify patients 
at high risk of stroke.27 However, the use of such risk 
models was not specified in any of the contributing tri-
als, and the selection of patients requiring revascular-
ization was left to the discretion of the investigators.
Our study has important limitations. First, random-
ized trials provide data from highly selected centers, 
operators, and patients. Procedural stroke risks may be 
higher in a real-world setting. Thus the external valid-
ity of the absolute risks observed in our study is lim-
ited. However, as the protocols of the trials remained 
largely unchanged throughout the studies, we strongly 
believe that the observed decline in treatment risk is 
real and externally valid. Second, the trials included 
in this meta-analysis were conducted between 2000 
and 2008. The procedural risk associated with carotid 
revascularization methods might have declined even 
further since 2008. Particularly in CAS, the most recent 
technical developments, such as stent designs with 
small open area between struts,28 reverse-flow protec-
tion systems,23 and direct transcervical access,29 were 
only achieved after completion of the 4 trials included 
in this meta-analysis, and many devices used in these 
trials are now outdated and no longer in use. Third, 
in the earliest years of enrollment (2000–2002), most 
patients included in this analysis were enrolled in either 
EVA-3S or SPACE. In addition, between 2007 and 
2008, enrollment only continued in ICSS and CREST, 
whereas EVA-3S and SPACE had completed their enroll-
ment. However, the adjustment for source trial included 
in all of our models should account for any differences 
between trials. In addition, in a post hoc analysis in 
which we excluded all patients from EVA-3S, the results 
remained essentially unchanged. Fourth, the results 
obtained in this analysis cannot necessarily be extrapo-
lated to a decline in procedural risk outside of clinical 
trials. Finally, because of the high percentage of miss-
ing values, we did not include days from QE to treat-
ment in our initial analysis even though this variable 
was shown to differentially influence the risk of carotid 
revascularization.30
CONCLUSIONS
Treatment of symptomatic carotid stenosis within the 
examined trials became safer over time. The reduction 
in stroke or death risk over time was driven by a signifi-
cant decline in procedural risks in patients treated with 
endarterectomy. Mechanisms underlying these findings 
remain to be determined.
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